Recent Updates
Recently added Catalysts
CTSO Negative Sentiment Score: 25/100

CYTOSORBENTS ALERT: Bragar Eagel & Squire, P.C. is Investigating Cytosorbents Corporation on Behalf of Cytosorbents Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating Cytosorbents Corporation on behalf of stockholders due to concerns regarding potential violations of federal securities laws. This follows the announcement that Cytosorbents' pivotal trial for DrugSorb®-ATR did not achieve its primary effectiveness endpoint for reducing perioperative bleeding. The company's stock price dropped significantly, indicating investor concerns about the trial outcomes and possible legal ramifications.

Market Sentiment Analysis

CONCERNS & RISKS

  • Cytosorbents' pivotal trial did not meet the primary effectiveness endpoint.
  • Following the trial results, the company's stock price fell by 33.44%.
  • Investigations by Bragar Eagel & Squire could indicate potential legal issues.

Full Press Release Details

NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cytosorbents Corporation (“Cytosorbents” or the “Company”) (NASDAQ: CTSO) on behalf of Cytosorbents stockholders. Our investigation concerns whether Cytosorbents has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On December 28, 2023, Cytosorbents issued a press release announcing that its pivotal trial investigating the ability of its device candidate, DrugSorb®-ATR, to reduce perioperative bleeding in patients on ticagrelor (Brilinta®, Brilique® - AstraZeneca) undergoing cardiothoracic surgery before completing the recommended washout period, "did not meet the primary effectiveness endpoint in the overall patient population that underwent different types of cardiac surgeries."
On this news, Cytosorbents' stock price fell $0.545 per share, or 33.44%, to close at $1.085 per share on December 28, 2023.
If you purchased or otherwise acquired Cytosorbents shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Frequently Asked Questions

What is the focus of Bragar Eagel & Squire's investigation?

The investigation examines potential claims against Cytosorbents for possible violations of federal securities laws and unlawful business practices.

What event caused a drop in Cytosorbents' stock price?

Cytosorbents' stock fell 33.44% after announcing its trial for DrugSorb®-ATR did not meet primary effectiveness endpoints.

How can affected Cytosorbents stockholders participate in the investigation?

Affected stockholders can contact Brandon Walker or Marion Passmore via email or phone for inquiries regarding their rights.

What type of firm is Bragar Eagel & Squire, P.C.?

Bragar Eagel & Squire, P.C. is a nationally recognized law firm representing investors in various legal matters.

Is there a cost to contact Bragar Eagel & Squire regarding the investigation?

There is no cost or obligation for stockholders to contact Bragar Eagel & Squire about the investigation.

Last updated: Jan 9, 2024